EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2019 to Jul 2024
EDAP TMS S.A. Retains Halliburton Investor Relations as Counsel
Company to Begin Enhanced Shareholder Communications and Outreach Program
LYON, France, Jan. 25 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP),
today announced it has retained Halliburton Investor Relations to assist the
company in its efforts to communicate with the investment community.
Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "We are
pleased to move forward in sharing our corporate strategy with the professional
investment community. In the last year, we have made substantial strides in our
operational success, including an objective of division profitability and
significant sales growth. Our new partnership with Halliburton Investor
Relations will enable us to more fully communicate our success and plans for
the future to a broader audience. Halliburton Investor Relations has a proven
track record of successful strategic investor communications programs for
publicly traded companies."
Alan Halliburton, President of Halliburton Investor Relations, said: "EDAP is a
successful, growing and innovative company but has remained undiscovered by the
investment community. We believe the company's success in its product lines and
future growth opportunities, especially the High Intensity Focused Ultrasound
(HIFU) treatment of prostate cancer where EDAP is a clear market leader, make
it a prime candidate for our strategic investor relations program. With
management, we will work to broaden EDAP's corporate visibility and help
achieve improved liquidity as well as a proper valuation of the company's stock
within the marketplace."
Based in Dallas, Texas, Halliburton Investor Relations was formed in 1990 to
provide a superior caliber of investor relations representation to publicly
traded companies. The firm develops strategic communications programs designed
to cultivate highly targeted relationships in the financial community and
improve the visibility of successful public companies to investors. For more
information, visit the company's Web site at http://www.halliburtonir.com/.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects. The
company is also developing this technology for the treatment of certain other
types of tumors. EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL).
For more information on the Company, contact the Investor Relations Dept by
phone at +33 (0)4 78 26 40 46 or see the Company's Web site at:
http://www.edap-tms.com/.
This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission.
Web sites: http://www.edap-tms.com
http://www.halliburtonir.com
DATASOURCE: EDAP TMS S.A.
CONTACT: EDAP TMS S.A. -- Hugues de Bantel - Philippe Chauveau, Blandine
Confort, +33-4-78-26-40-46, or Halliburton Investor Relations -- Matt Kreps -
Geralyn DeBusk, +1-972-458-8000